Filing Flows › PTC Therapeutics (PTCT) › Q2 2025
PTC Therapeutics (PTCT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
PTC Therapeutics (PTCT) reported revenue of $179M for the second quarter 2025 (Q2 2025), -4% from a year earlier and -85% from the quarter before. Operating margin was -19.5%, net loss $64.8M (36.3% of revenue).
PTC Therapeutics, Q2 2025: revenue $179M (-4% year over year), operating margin -19.5%, net loss $64.8M, operating cash flow −$58.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $179M | -85% | -4% |
| Operating profit | −$35.0M | -104% | — |
| Net earnings | −$64.8M | -107% | — |
| Operating cash flow | −$58.3M | -107% | — |
What changed
Revenue was $178.9M in Q2 2025, down 4% year over year and down 85% from the previous quarter. Translarna was the largest line at 33% of revenue. Emflaza lost $10.9M year over year (down 23%), 140% of the total change.
Operating costs exceeded revenue by $35.0M, an operating margin of -19.5%. Total costs fell 6% while revenue fell 4%. The fastest-growing cost line was SG&A (+23%). The quarter ended with a net loss of $64.8M, after a profit of $866.6M the previous quarter. Net interest and other expense of $36.1M was the main reason.
Operating cash flow was −$58.3M. Non-cash charges added back $7.6M of depreciation and amortization and $18.5M of share-based compensation. Working capital and other items used $19.6M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$59.6M.
Questions
What was PTC Therapeutics' revenue in the second quarter 2025?
PTC Therapeutics (PTCT) reported revenue of $179M for the second quarter 2025 (Q2 2025), -4% from a year earlier and -85% from the quarter before.
Was PTC Therapeutics profitable in the second quarter 2025?
Operating loss was $35.0M (-19.5% of revenue) and net loss $64.8M.
Source: PTC Therapeutics 10-Q on SEC EDGAR.